Dilated Cardiomyopathy : : From Genetics to Clinical Management.

Dilated Cardiomyopathy : : From Genetics to Clinical Management.

Saved in:
Bibliographic Details
:
Sinagra, Gianfranco.
TeilnehmendeR:
Merlo, Marco.
Pinamonti, Bruno.
Place / Publishing House:Cham : : Springer International Publishing AG,, 2019.
©2019.
Year of Publication:2019
Edition:1st ed.
Language:English
Online Access:
Physical Description:1 online resource (239 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Intro
  • Contents
  • Introduction
  • 1: Historical Terminology, Classifications, and Present Definition of DCM
  • 1.1 Dilated Cardiomyopathies: The Classification Pathway
  • 1.2 Genetic Dilated Cardiomyopathy and Etiological Classification
  • 1.3 Future Perspectives
  • References
  • 2: Epidemiology
  • 2.1 Towards Contemporary Clinical Epidemiology in Dilated Cardiomyopathy
  • 2.2 Genetics and Future Perspectives
  • References
  • 3: Pathophysiology
  • 3.1 Ventricular Remodeling in DCM
  • 3.2 Genetic Pathophysiology and New Possible Proteins Involved in DCM [2]
  • 3.3 Molecular Mechanisms of Cardiac Remodeling in HF [15]
  • References
  • 4: Etiological Definition and Diagnostic Work-Up
  • 4.1 Clinical Presentation
  • 4.2 Etiological Classification: A Critical Issue in Clinical Management of DCM
  • 4.2.1 Need of Reclassification of the Disease During Follow-Up
  • 4.3 Exclusion of Reversible Causes of Left Ventricular Dysfunction/Dilation
  • 4.4 Diagnostic Work-Up in New-Onset LV Dysfunction/Dilation: A "Red Flags" Approach
  • 4.4.1 Personal and Family History
  • 4.4.2 Symptoms and Physical Examination
  • 4.4.3 12 Lead Electrocardiogram
  • 4.4.4 Laboratory Tests
  • 4.4.4.1 Genetic Testing
  • 4.4.5 Echocardiography
  • 4.4.6 Cardiovascular Magnetic Resonance
  • 4.4.7 Cardiac Catheterizations and Procedures
  • 4.4.7.1 Coronary Angiogram
  • 4.4.7.2 Cardiac Catheterization
  • 4.4.7.3 Endomyocardial Biopsy
  • 4.5 Conclusions
  • References
  • 5: Genetics of Dilated Cardiomyopathy: Current Knowledge and Future Perspectives
  • 5.1 DCM-Associated Genes
  • 5.1.1 Titin
  • 5.1.2 Lamin A/C
  • 5.1.3 Structural Cytoskeleton Z-Disk Genes
  • 5.1.4 Desmosomal Genes
  • 5.1.5 Sarcomeric (Motor) Genes
  • 5.1.6 Ion Channel-Related Genes
  • 5.1.7 Other Genes
  • 5.2 Technical Issues in Genetic Sequencing.
  • 5.3 The Complexity in Variant Classification Process
  • 5.4 The External Modulation of Genotype: Environmental Triggers
  • 5.5 Evidence-Based Genotype-Phenotype Correlations
  • 5.5.1 Lamin A/C
  • 5.5.2 Titin
  • 5.5.3 Filamin C
  • 5.5.4 Insights from Clinical Presentation and Left Ventricular Reverse Remodeling (LVRR)
  • References
  • 6: Clinical Presentation, Spectrum of Disease, and Natural History
  • 6.1 Spectrum of Disease
  • 6.2 Clinical Presentation
  • 6.3 Natural History
  • References
  • 7: Role of Cardiac Imaging: Echocardiography
  • 7.1 Echocardiographic Features of Dilated Cardiomyopathy
  • 7.2 Role of New Echocardiographic Techniques
  • 7.3 Clinical Echocardiography in DCM: Advantages and Limitations in Clinical Practice
  • 7.4 Prognostic Role of Echocardiographic Data in DCM
  • References
  • 8: Role of Cardiac Imaging: Cardiac Magnetic Resonance and Cardiac Computed Tomography
  • 8.1 Cardiac Magnetic Resonance
  • 8.2 Diagnostic Accuracy
  • 8.3 Differential Diagnosis
  • 8.4 Myocarditis Presenting as Left Ventricular Dysfunction
  • 8.5 Other Secondary Forms of DCM
  • 8.6 Prognostic Stratification
  • 8.7 Macroscopic vs. Diffuse Fibrosis
  • 8.8 Strain Analysis
  • 8.9 Other Prognostic Indicators
  • 8.10 Computed Tomography
  • References
  • 9: Endomyocardial Biopsy
  • 9.1 Introduction
  • 9.2 Technique
  • 9.3 Complications
  • 9.4 Indications in DCM Scenarios
  • 9.5 Diagnosis of Myocarditis
  • 9.6 Examples of Endomyocardial Biopsy
  • 9.6.1 Case I (J.D.)
  • 9.6.2 Case II (C.P.)
  • 9.6.3 Case III (C.S.)
  • 9.6.4 Case IV (C.F.)
  • References
  • 10: Arrhythmias in Dilated Cardiomyopathy: Diagnosis and Treatment
  • 10.1 Burden and Kinds of Arrhythmias in Dilated Cardiomyopathy: Risk Stratification of Sudden Death
  • 10.1.1 Bradyrhythmias and Conduction Abnormalities
  • 10.1.2 Supraventricular Arrhythmias.
  • 10.1.3 Ventricular Arrhythmias
  • 10.1.4 Mechanisms
  • 10.1.5 Risk Stratification of Sudden Cardiac Death
  • 10.1.6 Role of Supraventricular and Ventricular Arrhythmias in Pathogenesis of DCM
  • 10.1.6.1 Definition and Pathophysiology
  • 10.1.6.2 Specific Clinical Pictures
  • 10.1.7 Management of Atrial Arrhythmias in Dilated Cardiomyopathy and Heart Failure
  • 10.1.8 Management of Ventricular Arrhythmias in Dilated Cardiomyopathy
  • 10.1.9 Antiarrhythmic Drug Therapy of Ventricular Arrhythmias
  • 10.1.10 Catheter Ablation of Ventricular Arrhythmias
  • 10.1.11 Characteristics of the Arrhythmogenic Substrate and Its Impact on Catheter Ablation Approach
  • 10.1.12 Role of ICD in DCM
  • References
  • 11: Regenerative Medicine and Biomarkers for Dilated Cardiomyopathy
  • 11.1 Strategies for Heart Regeneration
  • 11.1.1 Cell Therapy
  • 11.1.2 Gene Therapy
  • 11.2 Regenerative Approaches in Dilated Cardiomyopathy
  • 11.3 Biomarkers and Dilated Cardiomyopathy
  • References
  • 12: Prognostic Stratification and Importance of Follow-Up
  • 12.1 Prognosis of DCM: The Milestones of the Management
  • 12.2 Etiological Characterization as an Important Prognostic Factor
  • 12.3 DCM as a Dynamic Disease: The Importance of Follow-Up
  • 12.4 Left Ventricular Reverse Remodeling Beyond the Left Ventricle
  • 12.5 Prognostic Role of Cardiopulmonary Exercise Testing
  • 12.6 Arrhythmic Risk Stratification
  • 12.7 The "Apparent Healing" Phenomenon
  • 12.8 Uninterrupted Follow-Up and Continuous Reclassification of the Disease
  • References
  • 13: Current Management and Treatment
  • 13.1 Familial Screening Program
  • 13.2 Sport Activity Screening Program
  • 13.3 Medical Treatment
  • 13.4 Ventricular and Supraventricular Arrhythmias
  • 13.5 Implantable Cardioverter-Defibrillator
  • 13.6 Cardiac Resynchronization Therapy.
  • 13.7 Advanced Heart Failure, Mechanical Circulatory Support, Functional Mitral Regurgitation Correction, Heart Transplantation, and Palliative Care
  • References
  • 14: Unresolved Issues and Future Perspectives
  • 14.1 Toward a Personalized Medicine: A Genetic Approach
  • 14.2 The Challenge of Arrhythmic Stratification
  • 14.3 Toward Innovation in Therapy
  • References
  • 15: Dilated Cardiomyopathy at the Crossroad: Multidisciplinary Approach
  • 15.1 Sarcoidosis: Co-working with Pneumologists
  • 15.1.1 Treatment
  • 15.2 Autoimmune Cardiomyopathy: Co-working with Rheumatologists
  • 15.2.1 Systemic Lupus Erythematosus
  • 15.2.2 Treatment
  • 15.3 Infectious Disease and Cardiomyopathy: Co-working with Infectious Disease Specialist
  • 15.3.1 Chagas Cardiomyopathy
  • 15.3.2 Treatment
  • 15.3.3 Lyme Disease
  • 15.3.4 Treatment
  • 15.4 Dilated Cardiomyopathy Associated with Neuromuscular Diseases: Co-working with Neurologists
  • 15.5 Primary Iron-Overload Cardiomyopathy: Co-working with the Hematologists
  • 15.6 Cardiomyopathy Related to Chemotherapeutic Agents: Co-working with Oncologists
  • 15.6.1 Treatment
  • 15.7 Alcoholic Cardiomyopathy
  • 15.7.1 Treatment
  • References.

Similar Items